Article Text

FRI0371 A Comparison of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) TRIAL Design: Ways to Improve Positive Trials in Sle
  1. A. Miles1,
  2. J.E. Pope2
  1. 1Medicine, U of Toronto, Toronto
  2. 2Rheumatology, University of Western Ontario, London, Canada


Background Recent SLE RCTs were examined for potential design flaws and compared to rheumatoid arthritis (RA) RCT over the same time period to suggest modifications to SLE RCTs that could help improve the potential success rate of future SLE trials.

Objectives The objectives are to compare RA trials with SLE RCTs of biologics in order to learn how to design potentially successful future RCTs in SLE.

Methods RA and SLE biologics RCTs published between 2005 and July 2013 were identified using PubMed. Inclusion criteria, study design, outcome measures, sample size calculations, patient baseline characteristics steroid use in the protocol and results were extracted and compared.

Results Twenty-two RA RCTs and eight SLE RCTs were included. All RA RCTs used either a partial or continuous measure of improvement. SLE RCTs used SLEDAI, BILAG, SLAM, SRI and BICLA. RA trials were larger (543 vs 376 participants). Concomitant corticosteroid use was stable in 100% of RA trials while all SLE RCTs allowed dose tapering. RA trials were mostly in methotrexate or DMARD inadequate responders whereas SLE trials allowed for the presence or absence immunosuppressives within all trials. Sample sizes in RA were determined on a change in disease activity or proportion meeting a disease state. Positive trials were found in 100% of RA RCTs and 25% of SLE RCTs. Table provides some insights from RA to improve SLE trials.

Conclusions The potential insensitivity of SLE disease activity indices to partial improvements may result in type II errors in SLE RCTs. Varying concomitant pharmacotherapy, especially corticosteroid use, in SLE may blunt observed treatment effects. Steroid tapering should be considered a trial outcome in isolation. More realistic sample size calculations are needed in SLE.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.2728

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.